Long-term Clinical Outcomes of US-Guided High-Intensity Focused Ultrasound Ablation for Symptomatic Submucosal Fibroids: A Retrospective Comparison with Uterus–Sparing Surgery

Abstract

Uterus-sparing surgery and ultrasound (US)-guided high-intensity focused ultrasound (HIFU) ablation are both treatment options for symptomatic submucosal fibroids. No study had compared the long-term clinical outcomes between the two techniques. Therefore, the aim of this study was to compare the long-term clinical outcomes between US-guided HIFU ablation and uterus-sparing surgery for the treatment of symptomatic submucosal fibroids. A retrospective study was conducted on 245 women who were treated by US-guided HIFU ablation and 129 women who underwent uterus-sparing surgery for type I or type II symptomatic submucosal fibroids in a single institution from January 2007 to January 2015. The mean diameter of the fibroids was about 6 cm in both groups. They were followed up until December 2018. The symptom relief rate, symptom recurrence rate and incidence of major complications were compared between the two groups. The symptom relief rate was 95.9% for US-guided HIFU ablation and 89.1% for uterus-sparing surgery. The cumulative symptom recurrence rate at 1-, 3-, 5-, and 8 years was 1.7%, 6.8%, 9.4%, and 11.9% for US-guided HIFU ablation and 6.1%, 12.2%, 22.6%, and 27.8% for uterus-sparing surgery. Compared to uterus-sparing surgery group, US-guided HIFU ablation had a statistically higher symptom relief rate and a lower symptom recurrence rate (p < 0.05). The major complication rate was 3.1% in the uterus-sparing surgery group. No major complications occurred in the US-guided HIFU ablation group. This study showed that the long-term clinical outcomes of US-guided HIFU ablation may be better that of uterus-sparing surgery for the treatment of symptomatic submucosal fibroids. US-guided HIFU ablation may also be safer than uterus-sparing surgery. Further larger randomized trials are needed to confirm these findings.